NanoViricides Addresses Shareholders' Questions Regarding Price per Share
The Company's products and technologies address two important markets that are highly desired by institutional investors, Biopharma and Nanotechnology. NanoViricides believes it is now the very first company to bring a robust nanotechnology approach to antiviral medicines. "To develop nanomedicines that would be able to circulate in the body, seeking the pathogen, attacking and then destroying it. These new physical entities would be smaller than many viruses and almost a thousand times thinner than the width of a human hair. That was the intention of the inventor of our technology, Dr. Anil Diwan, when he started working on this project thirteen years ago," said Eugene Seymour, MD, MPH, Chief Executive Officer.
“The Company's core nanotechnology science addresses a number of very large viral disease markets”
He continued, "We believe we have the fastest growing and most robust drug development pipeline for a startup company in the pharmaceutical industry today. In our first year of operation, we have advanced three drugs into preclinical animal studies, with more to follow. We have accomplished so much in this first year that it would be hard to find a similar biopharma/nanotechnology company that has achieved so much in such a short period of time."
"The Company's core nanotechnology science addresses a number of very large viral disease markets," Mr. Leo Ehrlich, CFO, commented, "Management understands the importance of capital markets and its stockholders interest in value through a rising stock price. We will strive to make NanoViricides a part of industry specific indexes and fund holdings once we complete our SEC filing which is necessary to become a fully reporting company."
In March, San Francisco-based Global Crown Capital LLC announced the launch of the industry's first pure play nanotechnology index that represents the emerging nanotechnology industry which includes nanomedicine.
Other nanotechnology investment funds include, Harris and Harris (TINY), Punk Ziegel Nanotech Index, the Merrill Lynch Nanotech Index, the Lux Nanotech Index(TM), PowerShares Lux Nanotech Portfolio, and the Innovest Strategic Value Advisors Nanotech Index.
This release is part of management's desire to better communicate with its shareholders about its science and technology as it prepares to file with the SEC. The SEC filing, presently being prepared, will contain important information which clearly explains NanoViricides' accomplishments to date, the technology, its financials and the associated risk factors.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.